Back to top
more

VERADIGM INC (MDRX)

(Delayed Data from OTC)

$4.88 USD

4.88
2,281

+0.08 (1.67%)

Updated Aug 26, 2026 03:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (100 out of 247)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Nabaparna Bhattacharya headshot

MedTech Takes to Big Data Analytics: 3 Stocks Catch Eye

by Nabaparna Bhattacharya

Here we take a look at the major factors that are driving the importance of big data in the MedTech space.

    Zacks Equity Research

    Why Is Allscripts (MDRX) Down 11.3% Since its Last Earnings Report?

    by Zacks Equity Research

    Allscripts (MDRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

      Nabaparna Bhattacharya headshot

      Is the Tax Repeal Only Glitter and No Gold for MedTech?

      by Nabaparna Bhattacharya

      While the MedTech fraternity is hopeful about the latest MedTech tax repeal, we would like to draw your attention to the slump in share price and net margin figures following the tax's abolition in 2015.

        Zacks Equity Research

        Allscripts (MDRX) Launches Avenel to Revamp EHR Platform

        by Zacks Equity Research

        Allscripts' (MDRX) innovation team comes up with a user-friendly application, Avenel, to aid patients and clinicians through EHR.

          Zacks Equity Research

          Allscripts' (MDRX) Fundamentals Strong Amid Stiff Competition

          by Zacks Equity Research

          Allscripts' (MDRX) promising fourth-quarter results and international hold are encouraging. Integration risks and cutthroat competition are likely to mar prospects.

            Zacks Equity Research

            Allscripts (MDRX) Q4 Earnings Meet, Revenues Beat Estimates

            by Zacks Equity Research

            Solid year-over-year growth in Client Services revenues drove Allscripts in Q4.

              Zacks Equity Research

              Allscripts (MDRX) Q3 Earnings Meet, Revenues Beat Estimates

              by Zacks Equity Research

              Allscripts' (MDRX) solid guidance for 2017 and a bullish long-term outlook are key highlights of Q3. The expansion in margins is encouraging.

                Zacks Equity Research

                Allscripts Rides High on Product Launches Amid Rising Costs

                by Zacks Equity Research

                Management at Allscripts Healthcare (MDRX) is focused on various restructuring initiatives, research and development plans and launch of exclusive products.

                  Zacks Equity Research

                  Allscripts' Latest Initiative Eradicates Price Ambiguity

                  by Zacks Equity Research

                  Lately, Allscripts' (MDRX) management has been focusing on various restructuring initiatives, research and development plans and launch of exclusive products.

                    Zacks Equity Research

                    Allscripts' (MDRX) dbMotion Platform Selected by SWSPHN

                    by Zacks Equity Research

                    The latest development is a significant addition to Allscripts' (MDRX) dbMotion Solution platform customer base. The company is poised to benefit from opportunities in the Asia-Pacific market.